Best Life Sciences Companies in Newark, United States

Developer of gene-based therapies for cancer treatment. It offers a CRISPR/Cas molecule based on gene editing that disables the genome of a tumor cell and targets the NRF2 gene for the treatment of solid tumors.

Funding rounds

• Aug 2025Series A$1M
• Jan 2024Seed—
• Oct 2023Seed—
• Jun 2022Seed$6.5M

Founders & team

Eric KmiecCEO

Investors

Cortado Ventures, Delaware Office of Work-based Learning, Delaware

Developing personalized neurorehabilitation exergames. The company creates fun, engaging exergames to improve hand and arm function in children and adults. These products utilize technology and research in brain plasticity, offering gamified rehabilitation with remote or in-person clinician supervision and progress tracking. The system is designed for use in various settings, including hospitals, outpatient centers, schools, and homes, providing a cost-effective solution to improve patient outcomes. The exergames aim to enhance rehabilitation and improve quality of life for individuals with disabilities.

Funding rounds

• May 2025Grant (prize money)$575K
• Sep 2024Grant (prize money)$287.5K
• Jun 2022Grant (prize money)$100K
• May 2021Grant (prize money)$276K

Founders & team

Amanda GrossCo-Founder & CTO

Investors

HHS

Developer of high-throughput NGS instrument for research. The company has developed a fundamentally new sequencing architecture including completely different flow cell engineering, sequencing chemistry, and machine learning. The company has currently in an early access program for the UG 100, its first high-throughput NGS instrument using this new technology architecture which enables customers to generate high-quality sequencing data.

Funding rounds

• May 2022Series D$600M
• May 2020Grant (prize money)$2M
• May 2019Grant (prize money)$2.2M

Founders & team

Gilad AlmogyCo-Founder & CEO

Investors

Andreessen Horowitz, Founders Fund, Khosla Ventures, General Atlantic, D1 Capital Partners, Lightspeed Venture Partners

Tech stack

AstroCloudflareGoogle AnalyticsGoogle Tag ManagerGsapHsts

Developer of drug screening device for medical exams and law enforcement. It provides The Integrity-1 Analysis System, a microfluidic test cartridge for toxicological testing that enables the recirculation of both the sample and chemicals over a sensor.

Funding rounds

• Jan 2025Grant (prize money)$275.8K
• 2022Seed—

Founders & team

Glennon SimmonsCo-Founder & CEOIgor MuravchikCo-Founder

Investors

HAX, HHS, NextFab Ventures

Provider of hydrogel for surgery and wound care. It focuses on tissue sealant, hemostat, and biomedical adhesive markets. It offers a biocompatible and biodegradable hydrogel with various types of surgery and wound care applications. The products also include topical hemostat, internal hemostat, and wound care. Its products are offered in various forms, such as injectable liquid hydrogel and lyophilized foams.

Funding rounds

• Jul 2024Seed$500K
• May 2019Seed$1.2M
• May 2014Grant (prize money)$1.5M
• Dec 2011Seed$300K

Founders & team

Richard RussoPresident & Chief Executive Officer

Investors

Central Texas Angel Network, HHS, NIH, Healthcare Ventures, Rho Capital Partners, Keiretsu Forum

Tech stack

WordpressMysqlPhpNginxOpenrestyHsts

Sepax Technologies develops and provides solutions, in the form of products and services, for chromatographic biomolecular separation. The company has a growing range of products and technologies in the areas of particle synthesis, surface modification, LC column packing, bulk media production, and purification process development, and covers all major modalities of chromatographic separation including size exclusion, ion exchange, hydrophobic interaction, ion exclusion, UHPLC, reversed phase, mixed-mode phase, HILIC, among others. The company's services include analytical chromatography, prep purification, custom resin and custom surface coatings.

Funding rounds

• Nov 2021Series D$78.4M
• Mar 2021Series C$30.9M
• Jun 2018Series A—

Founders & team

Sean HuangCEO

Investors

Gan & Lee Pharmaceutical, Sinopharm Capital, Sherpa Healthcare Partners, Hillhouse Ventures, kexingholdings, CPE

Tech stack

Cart FunctionalityPhpNginxSelect2JqueryGoogle Tag Manager

Developer of therapeutics for cancer treatment. It offers lead drug candidate, milademetan, is an oral small molecule, inhibitor of mouse double minute 2 (MDM2) in patients with liposarcoma and other MDM2 - dependent cancers.

Funding rounds

• Sep 2020Series B$72.6M
• Sep 2020Conventional Debt—
• May 2018Series A$18.4M
• Nov 2017Seed$1M

Founders & team

Robert DoebeleCo-FounderAvanish VellankiCo-Founder & CEO

Investors

Perceptive Advisors, BVF Partners, UniServices, Boxer Capital, Samsara BioCapital, Janus Henderson Investors

Developer of neurotoxin aesthetic and therapeutic products for skin treatments. It focused on developing innovative products in the aesthetic medicine and personal wellness categories. It has developed a platform technology that enables the delivery of large macromolecules and other potent molecules across the skin. Its aesthetics pipeline includes RT001 for lateral canthal lines and RT002 for glabellar lines. It has the same products as therapies for Hyperhidrosis and Cervical Dystonia.

Funding rounds

• Oct 2013Series E$10M
• Feb 2013Series E$33M
• Jan 2013Series D$63.4M
• Feb 2011Series C$5M

Founders & team

Mark FoleyChief Executive Officer

Investors

Delphi Ventures, EW Healthcare Partners, Quintiles, Technology Partners, Shepherd Ventures, Palo Alto Investors

Tech stack

WordpressMysqlPhpKadence Wp KadenceWp RocketUltimate Addons For Elementor

Oraya Therapeutics, develops non-invasive therapies for diseases of the eye. Oraya's device is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration (wet AMD). It uses low-voltage X-Ray source with robotics, a laser-guided positioning system, and a patented methodology for eye stabilization and tracking. The procedure is delivered in an outpatient setting, averaging 20 minutes and requiring no post-treatment recovery period before resuming normal activity. In 2015, Oraya signed an agreement with Carl Zeiss where the latter would provide funding to Oraya, in return for rights reaching upto a majority stake in 2 years.

Comprehensive healthcare network offering diverse medical services and personalized patient care. This organization provides a wide array of medical services, including dentistry with smile design and dental implants, orthodontics with invisible aligners, online psychology services, and advanced medical imaging for early cancer detection. They focus on functional medicine, suerotherapy, and various specialized treatments like breast reduction surgery. The network emphasizes patient-centered care, offering resources such as a physician finder, employment opportunities, and consumer health resources. They aim to improve patient well-being through personalized, science-based approaches, promoting optimal health and emotional wellness. They offer both surgical and non-surgical cosmetic procedures, and also provide community programs, classes, and workshops to enrich personal health.

Symbiomix is a late-stage, privately-held biopharmaceutical company with a focus on women's health. The company is focused on developing treatments for prevalent gynecological infections. The Company's lead investigational drug Solosec (secnidazole in oral granules form), a 5-nitroimidazole antibiotic, is anticipated to be the first and only single-dose oral treatment approved for bacterial vaginosis (BV). Solosec has been designated a Qualified Infectious Disease Product (QIDP) by the FDA for the treatment of BV and has received Fast Track designation from the agency in 2015. Solosec was approved by the FDA for BV with benefits of 10-year exclusivity. The company was acquired by the American arm of India-based Lupin in October 2017.

Developer of a transnational research platform for biomarker analysis. The company's proprietary product includes RNAscope technology that is capable of detecting and quantifying RNA biomarkers in situ at single-molecule sensitivity. The company also provides clinical-grade assay development and biomarker analysis services to speed up biomarker validation and companion diagnostic development services. The company's technology platform helps in the development of targeted therapies for cancer and other diseases. Its product portfolio includes RNAscope probes, reagent kits, hybridization systems, and software.